Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa

Lancet

Volumn 362, Issue 9384, 2003, Pages 617-619

  Marin, David ^a   Marktel, Sarah ^a   Szydlo, Richard ^a   Klein, John P ^b   Bua, Marco ^a   Foot, Nicola ^a   Olavarria, Eduardo ^a   Shepherd, Pat ^c   Kanfer, Edward ^a   Goldman, John M ^a   Apperley, Jane F ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BUSULFAN; HYDROXYUREA; IMATINIB;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT; PRIORITY JOURNAL; RISK; SURVIVAL; TREATMENT FAILURE;

EID: 0041966018     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14182-7     Document Type: Article

References (5)

1. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 344:2001;1031-1037.
2. Kantarjian H., Sawyers C., Hochhaus A., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 346:2002;645-652.
3. Allan N.C., Richards S.M., Shepherd P.C. UK Medical Research Council randomised, multicentre trial of interferon-alfa n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet. 345:1995;1392-1397.
4. Shah N., Nicoll J., Nagar B., et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2:2002;117-125.
5. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 348:2003;994-1004.